Inhibition of IκB kinase by thalidomide increases hepatitis C virus RNA replication

Area of Science:

• Hepatology
• Virology
• Immunology

Background:

• Hepatic fibrosis progression in chronic liver disease is linked to elevated interleukin-8 (IL-8).
• Hepatitis C virus (HCV) infection involves IL-8 and nuclear factor kappa B (NF-κB) pathways.
• Thalidomide's effect on HCV replication is not well understood, despite its use in reducing liver inflammation.

Purpose of the Study:

• To investigate the impact of thalidomide on HCV replication in vitro.
• To elucidate the role of the NF-κB signaling pathway in regulating HCV RNA replication.

Main Methods:

• HCV replication was assessed in Huh-7 cells treated with thalidomide and NF-κB inhibitors.
• Changes in IL-8, NF-κB activity, IκB kinase (IKK) activation, and NF-κB(p65)/RelA protein levels were measured.
• Ectopic expression of IKKα and NF-κB(p65)/RelA was used to modulate signaling pathways.

Main Results:

• Thalidomide reduced IL-8 and NF-κB activity but significantly increased HCV replication (17-fold).
• NF-κB inhibitors (wedelolactone, NF-κB activation inhibitor-1) mimicked thalidomide's effect, increasing HCV RNA (18-19 fold).
• Inhibition of IKK activation and NF-κB signaling augmented HCV RNA replication, while restoring NF-κB activity reduced it.

Conclusions:

• HCV RNA replication is significantly enhanced by the inhibition of IKK activation and subsequent NF-κB signaling.
• The NF-κB signaling pathway plays a critical role in controlling HCV replication.
• Targeting NF-κB activity may offer therapeutic strategies for managing HCV infection.